Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook January 14, 2025
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases November 4, 2024
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 12, 2024
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma June 26, 2024
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting April 24, 2024
